Claire M Edwards

List of Publications by Year
in descending order

54 papers	2,133 citations	236833 25 h-index	233338 45 g-index
58 all docs	58 docs citations	58 times ranked	3213 citing authors

#	Article	IF	Citations
1	The pathogenesis of the bone disease of multiple myeloma. Bone, 2008, 42, 1007-1013.	1.4	154
2	Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood, 2008, 111, 2833-2842.	0.6	150
3	Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. British Journal of Cancer, 2017, 116, 227-236.	2.9	132
4	Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood, 2011, 118, 5872-5882.	0.6	124
5	Eph Receptors and Ephrin Signaling Pathways: A Role in Bone Homeostasis. International Journal of Medical Sciences, 2008, 5, 263-272.	1.1	114
6	Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells. PLoS ONE, 2012, 7, e48871.	1.1	105
7	Role of osteoprotegerin (OPG) in cancer. Clinical Science, 2006, 110, 279-291.	1.8	98
8	A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biology Direct, 2010, 5, 28.	1.9	96
9	LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1451-1462.	6.7	89
10	Contributions of the Host Microenvironment to Cancer-Induced Bone Disease. Cancer Research, 2014, 74, 1625-1631.	0.4	81
11	Metformin and Prostate Cancer: a New Role for an Old Drug. Current Urology Reports, 2017, 18, 46.	1.0	77
12	Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1. Cancer Research, 2012, 72, 2183-2189.	0.4	70
13	Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. International Journal of Cancer, 2006, 119, 1254-1261.	2.3	65
14	Diet-induced obesity promotes a myeloma-like condition in vivo. Leukemia, 2015, 29, 507-510.	3.3	56
15	Bone Marrow Adipose Tissue: A New Player in Cancer Metastasis to Bone. Frontiers in Endocrinology, 2016, 7, 90.	1.5	52
16	Tumorâ€"host cell interactions in the bone disease of myeloma. Bone, 2011, 48, 121-128.	1.4	49
17	Gr-1+CD11b+ myeloid-derived suppressor cells: Formidable partners in tumor metastasis. Journal of Bone and Mineral Research, 2010, 25, 1701-1706.	3.1	47
18	Myeloma Cells Downâ€Regulate Adiponectin in Bone Marrow Adipocytes Via TNFâ€Alpha. Journal of Bone and Mineral Research, 2020, 35, 942-955.	3.1	47

#	Article	IF	Citations
19	Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease. Nature Communications, 2019, 10, 4533.	5.8	46
20	Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma. Journal of Cellular Physiology, 2018, 233, 9159-9166.	2.0	45
21	Preclinical animal models of multiple myeloma. BoneKEy Reports, 2016, 5, 772.	2.7	41
22	Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. American Journal of Hematology, 2009, 84, 268-272.	2.0	40
23	A murine model of myeloma that allows genetic manipulation of the host microenvironment. DMM Disease Models and Mechanisms, 2009, 2, 604-611.	1.2	39
24	The role of bone marrow adipocytes in bone metastasis. Journal of Bone Oncology, 2016, 5, 121-123.	1.0	33
25	Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Molecular Cancer Therapeutics, 2007, 6, 3219-3228.	1.9	25
26	New approaches to targeting the bone marrow microenvironment in multiple myeloma. Current Opinion in Pharmacology, 2016, 28, 43-49.	1.7	25
27	Bone marrow adiposity and multiple myeloma. Bone, 2019, 118, 42-46.	1.4	22
28	Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia, 2007, 21, 805-812.	3.3	21
29	Apomineâ„¢, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. International Journal of Cancer, 2007, 120, 1657-1663.	2.3	20
30	Small Animal Video Tracking for Activity and Path Analysis Using a Novel Open-Source Multi-Platform Application (AnimApp). Scientific Reports, 2019, 9, 12343.	1.6	19
31	Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival. Science Advances, 2022, 8, eabf9096.	4.7	19
32	BTK inhibition in myeloma: targeting the seed and the soil. Blood, 2012, 120, 1757-1759.	0.6	14
33	A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo. Molecular Cancer, 2017, 16, 49.	7.9	14
34	Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment. Scientific Reports, 2019, 9, 14189.	1.6	14
35	Wnt signaling: bone's defense against myeloma. Blood, 2008, 112, 216-217.	0.6	12
36	The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease. Current Osteoporosis Reports, 2016, 14, 170-177.	1.5	11

#	Article	IF	Citations
37	Metabolism in the Tumour-Bone Microenvironment. Current Osteoporosis Reports, 2021, 19, 494-499.	1.5	10
38	Apomine Enhances the Antitumor Effects of Lovastatin on Myeloma Cells by Down-Regulating 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 228-235.	1.3	8
39	Novel therapeutic targets in myeloma bone disease. British Journal of Pharmacology, 2014, 171, 3765-3776.	2.7	8
40	Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis. Current Osteoporosis Reports, 2018, 16, 635-641.	1.5	6
41	Morphogens and growth factor signalling in the myeloma bone-lining niche. Cellular and Molecular Life Sciences, 2021, 78, 4085-4093.	2.4	6
42	The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo. Translational Oncology, 2022, 15, 101301.	1.7	6
43	Advances in the management of myeloma bone disease. Expert Opinion on Pharmacotherapy, 2005, 6, 2781-2791.	0.9	5
44	Modeling the Human Boneâ€"Tumor Niche: Reducing and Replacing the Need for Animal Data. JBMR Plus, 2020, 4, e10356.	1.3	5
45	Animal Models of Multiple Myeloma. Methods in Molecular Biology, 2019, 1914, 349-360.	0.4	3
46	Myeloma and marrow adiposity: Unanswered questions and future directions. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101541.	2.2	3
47	Osteoclasts in Myeloma Are Derived from Gr-1+CD11b+ Myeloid Immune Suppressor Cells of the Bone Marrow Niche in Vivo. Blood, 2008, 112, 736-736.	0.6	2
48	Protein Profiling in Myeloma In Vivo; Effects of Bortezomib in a Mouse Model of Myeloma.. Blood, 2007, 110, 255-255.	0.6	2
49	Proteasome Inhibitors and the Wnt Signaling Pathway in Myeloma Bone Disease. , 2010, , 211-229.		1
50	Advances in the molecular pharmacology of bone and cancerâ€related bone diseases. British Journal of Pharmacology, 2021, 178, 1889-1890.	2.7	0
51	Biological relationship between bone and myeloma cells. , 2022, , 1005-1017.		0
52	Transcriptome Profiling of the Myeloma-Bone Niche Identifies BMP Signaling Role in Bone Destruction and Niche Maintenance, and Potential As a Therapeutic Target. Blood, 2016, 128, 483-483.	0.6	0
53	Bone Marrow Adipose Tissue and Cancer. , 2020, , 265-272.		0
54	Editorial â€" Cancer and Bone special issue. Bone, 2022, 158, 116369.	1.4	0